Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Alpha Cognition Inc.

Alpha Cognition Inc. Reports First Quarter 2025 Financial Results and Operating Overview
From Alpha Cognition Inc.
Via Business Wire
Tickers ACOG
Alpha Cognition to Report First Quarter 2025 Financial Results and Operating Overview
From Alpha Cognition Inc.
Via Business Wire
Tickers ACOG
Alpha Cognition Strengthens Its Leadership Team with Appointment of Robert Wills to Board of Directors and Announces Departure of Existing Director John Havens
From Alpha Cognition Inc.
Via Business Wire
Tickers ACOG
Alpha Cognition Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Operating Overview
From Alpha Cognition Inc.
Via Business Wire
Tickers ACOG
Alpha Cognition to Report Fourth Quarter and Full Year 2024 Financial Results and Operating Overview
From Alpha Cognition Inc.
Via Business Wire
Tickers ACOG
Alpha Cognition Announces the Commercial Launch of ZUNVEYL (Benzgalantamine) for the Treatment of Mild to Moderate Alzheimer’s Disease
From Alpha Cognition Inc.
Via Business Wire
Tickers ACOG
Alpha Cognition Secures Additional U.S. Patent for ZUNVEYL (benzgalantamine) in the Treatment of Mild to Moderate Alzheimer’s disease
From Alpha Cognition Inc.
Via Business Wire
Tickers ACOG
Alpha Cognition Expands Commercial and Medical Teams with Key Leadership Hires to Support the Launch of ZUNVEYL
From Alpha Cognition Inc.
Via Business Wire
Tickers ACOG
Alpha Cognition to Present Q1 2025 ZUNVEYL (benzgalantamine) Launch Strategy Targeting the $2 Billion U.S. Alzheimer’s Long-Term Care Market During Investor Update Call
From Alpha Cognition Inc.
Via Business Wire
Tickers ACOG
Alpha Cognition Announces Partial Exercise of Over-allotment Option
From Alpha Cognition Inc.
Via Business Wire
Tickers ACOG CSE:ACOG
Alpha Cognition Announces Voluntary Delisting from CSE
From Alpha Cognition Inc.
Via Business Wire
Tickers ACOG CSE:ACOG
Alpha Cognition Announces Positive Interim Pre-Clinical Data for ALPHA-1062 Use in a Military Relevant Model of Repetitive Mild Traumatic Brain Injury
From Alpha Cognition Inc.
Via Business Wire
Tickers ACOG CSE:ACOG
Alpha Cognition Announces Financial Results for the Second Quarter and Six Months Ended June 2024 and Provides Corporate Update
From Alpha Cognition Inc.
Via Business Wire
Tickers ACOG CSE:ACOG
Alpha Cognition Announces Pricing of $50 Million Upsized Public Offering and Nasdaq Listing
From Alpha Cognition Inc.
Via Business Wire
Tickers ACOG CSE:ACOG
Alpha Cognition Announces Proposed Financing and Share Consolidation in connection with Nasdaq Uplisting
From Alpha Cognition Inc.
Via Business Wire
Tickers ACOGF CSE:ACOG
Alpha Cognition Announces Appointment of VP Finance and Accounting
From Alpha Cognition Inc.
Via Business Wire
Tickers ACOGF CSE:ACOG
Alpha Cognition Receives Notice of Allowance for Composition-of-Matter Patent for ZUNVEYLTM for Mild to Moderate Alzheimer’s Disease
From Alpha Cognition Inc.
Via Business Wire
Tickers ACOGF CSE:ACOG
Alpha Cognition Announces Change of Officer
From Alpha Cognition Inc.
Via Business Wire
Tickers ACOGF CSE:ACOG
Alpha Cognition Announces Completion of $4.545 Million (USD) Convertible Note and Warrants Bridge Financing
From Alpha Cognition Inc.
Via Business Wire
Tickers ACOGF CSE:ACOG
Alpha Cognition Receives Notice of Allowance for Composition-of-Matter Patent for ZUNVEYL® for Mild to Moderate Alzheimer’s Disease
From Alpha Cognition Inc.
Via Business Wire
Tickers ACOGF CSE:ACOG
Alpha Cognition, Inc. On Track to Secure Financing for Continued Growth
From Alpha Cognition Inc.
Via Business Wire
Tickers ACOGF CSE:ACOG
Alpha Cognition Announces Financial Results for the Second Quarter and Six Months Ended June 2024 and Provides Corporate Update
From Alpha Cognition Inc.
Via Business Wire
Tickers ACOG CSE:ACOG
Alpha Cognition’s Oral Therapy ZUNVEYL® Receives FDA Approval to Treat Alzheimer's Disease
From Alpha Cognition Inc.
Via Business Wire
Tickers ACOGF CSE:ACOG
Alpha Cognition Files U.S. Patent Application Covering an ALPHA-1062 Oral Formulation to Treat Mild to Moderate Alzheimer’s Disease
From Alpha Cognition Inc.
Via Business Wire
Tickers ACOGF CSE:ACOG
Alpha Cognition Provides Business Update
From Alpha Cognition Inc.
Via Business Wire
Tickers ACOGF CSE:ACOG
Alpha Cognition Announces Final Closing of Private Placement Offering and Completion of the Overallotment
From Alpha Cognition Inc.
Via Business Wire
Tickers ACOGF CSE:ACOG
Alpha Cognition Announces Fourth Closing of Private Placement and Continuation of the Offering
From Alpha Cognition Inc.
Via Business Wire
Tickers ACOGF CSE:ACOG
Alpha Cognition Announces FDA Acceptance of New Drug Application for ALPHA-1062 for Mild-to-Moderate Alzheimer’s Disease
From Alpha Cognition Inc.
Via Business Wire
Tickers ACOGF CSE:ACOG
Alpha Cognition Announces Amended Terms of Private Placement and Continuation of the Offering
From Alpha Cognition Inc.
Via Business Wire
Tickers ACOGF CSE:ACOG
Alpha Cognition Announces Second Closing of Private Placement and Continuation of the Offering
From Alpha Cognition Inc.
Via Business Wire
Tickers ACOGF CSE:ACOG
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.